Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of Oral BAY1161909 in Combination With Weekly Intravenous Paclitaxel Given in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies

NCT02138812 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT02138812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02138812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of Oral BAY1161909 in Combination With Weekly Intravenous Paclitaxel Given in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Terminated
Start date
May 9, 2014
Completion date
October 2, 2017
Enrollment
69 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

medical oncology